Earnings summaries and quarterly performance for PROTHENA CORP PUBLIC LTD.
Executive leadership at PROTHENA CORP PUBLIC LTD.
Gene G. Kinney
Detailed
President and Chief Executive Officer
CEO
BS
Brandon S. Smith
Detailed
Chief Operating Officer
MJ
Michael J. Malecek
Detailed
Chief Legal Officer & Company Secretary
TB
Tran B. Nguyen
Detailed
Chief Strategy Officer and Chief Financial Officer
WM
Wagner M. Zago
Detailed
Chief Scientific Officer
Board of directors at PROTHENA CORP PUBLIC LTD.
Research analysts who have asked questions during PROTHENA CORP PUBLIC LTD earnings calls.
Brian Abrahams
RBC Capital Markets
5 questions for PRTA
Also covers: ACAD, ATAI, BCRX +19 more
JB
Jason Butler
JMP Citizens
5 questions for PRTA
Also covers: ACAD, AQST, ATHA +10 more
Michael Yee
Jefferies
5 questions for PRTA
Also covers: ABBV, ALLO, AMGN +19 more
Jay Olson
Oppenheimer & Co. Inc.
4 questions for PRTA
Also covers: ACAD, AMGN, BIIB +23 more
RL
Rudy Li
Chardan Capital Markets
4 questions for PRTA
Also covers: ACAD, ALKS, MNMD +2 more
TA
Tazeen Ahmad
Bank of America
4 questions for PRTA
Also covers: ACAD, ALNY, APLS +22 more
UR
Umer Raffat
Evercore ISI
4 questions for PRTA
Also covers: ALKS, AMGN, BHC +15 more
CD
Charles Duncan
Cantor Fitzgerald & Co.
3 questions for PRTA
Also covers: ACAD, ALKS, ATAI +12 more
ES
Emma Seymour
Leerink Partners
3 questions for PRTA
Michael DiFiore
Evercore ISI
2 questions for PRTA
Also covers: AMGN, AMLX, BIIB +9 more
AD
Alexa Deemer
Cantor Fitzgerald
1 question for PRTA
Also covers: IVVD, SPRY, TRVI
ES
Eric Schmidt
Cantor Fitzgerald & Co.
1 question for PRTA
Also covers: ADCT, AGIO, BEAM +11 more
NB
Neena Bitritto-Garg
Deutsche Bank
1 question for PRTA
Also covers: ATAI, PASG
NJ
Nevin Jacob
RBC Capital Markets
1 question for PRTA
SR
Shannon Rahimi
Piper Sandler
1 question for PRTA
YR
Yasmin Rahimi
Piper Sandler
1 question for PRTA
Also covers: PRAX
Recent press releases and 8-K filings for PRTA.
Prothena Announces Share Repurchase Plan
PRTA
Share Buyback
- Prothena Corporation plc announced on February 27, 2026, that its Board of Directors authorized a Share Repurchase Plan for up to $100.0 million of its outstanding ordinary shares. This plan will expire on December 31, 2026, and is discretionary, meaning it does not obligate the company to acquire any shares and may be suspended or discontinued at any time.
- As of December 31, 2025, Prothena reported $308.4 million in cash, cash equivalents, and restricted cash, and no debt. The company expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash, excluding any potential purchases under this plan.
17 hours ago
Prothena Announces Up to $100 Million Share Repurchase Plan
PRTA
Share Buyback
Guidance Update
- Prothena Corporation plc has announced that its Board of Directors authorized a Share Repurchase Plan for up to $100.0 million of the Company’s outstanding ordinary shares.
- The Share Repurchase Plan will expire on December 31, 2026, and the timing, number of shares, and prices paid are discretionary and subject to various conditions.
- As of December 31, 2025, Prothena reported $308.4 million in cash, cash equivalents, and restricted cash, with no debt.
- Excluding potential purchases under this plan, Prothena expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash.
- The company also anticipates the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026.
17 hours ago
Prothena Corp Public Ltd Reports Q4 2025 Results and Provides 2026 Outlook
PRTA
Earnings
Guidance Update
Share Buyback
- Prothena ended 2025 with a cash and restricted cash balance of $308.4 million and reported a net loss of $244.1 million.
- The company expects net cash used in operating and investing activities in 2026 to be between $50 million-$55 million, projecting to end 2026 with approximately $255 million in cash.
- Two partner programs, prasinezumab (Roche) and coramitug (Novo Nordisk), advanced into Phase III clinical trials in 2025, with primary completion expected in 2029.
- Prothena has the potential to earn up to $105 million in aggregate clinical milestone payments in 2026 from its partners, and up to approximately $3 billion in total future milestone payments from its four clinical programs.
- A share redemption program has been confirmed and is expected to be implemented in 2026.
Feb 19, 2026, 9:30 PM
Prothena Reports Q4 2025 Financial Results and 2026 Outlook
PRTA
Earnings
Guidance Update
Share Buyback
- Prothena reported net cash used in operating and investing activities of $163.7 million and a net loss of $244.1 million for Q4 2025, concluding the year with a cash, cash equivalents, and restricted cash balance of $308.4 million.
- For fiscal year 2026, the company projects net cash used in operating and investing activities between $50 million and $55 million, with an anticipated year-end cash balance of approximately $255 million.
- In 2025, prasinezumab (Roche) and coramitug (Novo Nordisk) advanced into Phase 3 clinical trials, with primary completion for both expected in 2029.
- Prothena has the potential to earn up to $105 million in aggregate clinical milestone payments in 2026 from its partners and plans to implement a share redemption program.
Feb 19, 2026, 9:30 PM
Prothena Announces Q4 and Full-Year 2025 Financial Results and 2026 Outlook
PRTA
Earnings
Guidance Update
Share Buyback
- Prothena reported a net loss of $244.1 million and net cash used in operating and investing activities of $163.7 million for fiscal year 2025, concluding the year with $308.4 million in cash, cash equivalents, and restricted cash as of December 31, 2025.
- For fiscal year 2026, the company forecasts a net loss of $67 million to $72 million and net cash used in operating and investing activities of $50 million to $55 million, with an estimated year-end cash balance of $255 million. This guidance excludes up to $105 million in potential clinical milestone payments from strategic partners.
- In 2025, Prasinezumab for Parkinson's disease and Coramitug for ATTR-CM both advanced to Phase 3.
- Prothena anticipates potential clinical milestones in 2026 from Coramitug (Phase 3 enrollment) and PRX019 (BMS decision following Phase 1 completion).
- The company also obtained necessary shareholder approvals to support a share redemption program in 2026.
Feb 19, 2026, 9:30 PM
Prothena Reports Q4 and Full Year 2025 Financial Results, Provides 2026 Guidance, and Highlights Pipeline Progress
PRTA
Earnings
Guidance Update
New Projects/Investments
- Prothena reported $308.4 million in cash, cash equivalents, and restricted cash as of December 31, 2025, which was favorable to its guidance of $298 million. The net cash used in operating and investing activities for 2025 was $163.7 million, also favorable to guidance.
- For 2026, the company projects net cash used in operating and investing activities between $50 million-$55 million, with an anticipated year-end cash balance of approximately $255 million. This guidance excludes up to $105 million in potential clinical milestone payments from strategic partners.
- In 2025, two key partner programs, prasinezumab (Roche) and coramitug (Novo Nordisk), advanced into Phase 3 clinical trials, with primary completion for both anticipated in 2029. Additionally, the Phase 2 TargetTau-1 trial for BMS-986446 (Bristol Myers Squibb) was fully enrolled, with completion expected in the first half of 2027.
- Prothena's four partner clinical programs collectively hold the potential for up to approximately $3 billion in future milestone payments, alongside royalties. A key 2026 priority is to capture value from these partnerships and implement a share redemption program.
Feb 19, 2026, 9:30 PM
Prothena Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance
PRTA
Earnings
Guidance Update
Share Buyback
- Prothena reported a net loss of $244.1 million and total revenue of $9.7 million for the full year 2025, compared to a net loss of $122.3 million and total revenue of $135.2 million for the full year 2024.
- The company concluded 2025 with $308.4 million in cash, cash equivalents, and restricted cash.
- For full year 2026, Prothena projects net cash used in operating and investing activities of $50 to $55 million and an estimated year-end cash balance of approximately $255 million (midpoint). This guidance excludes up to $105 million in potential clinical milestone payments from strategic partners.
- In Q4 2025, partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, respectively, with primary completion anticipated in 2029 for both. Bristol Myers Squibb also fully enrolled the Phase 2 TargetTau-1 trial for BMS-986446.
- Shareholders approved a capital reduction in November 2025 to create distributable reserves, enabling flexibility for a potential share redemption program in 2026.
Feb 19, 2026, 9:05 PM
Prothena Provides Update on Pipeline Progress and 2026 Milestones
PRTA
New Projects/Investments
Guidance Update
Share Buyback
- Prothena has two Phase 3 programs: prasunezumab for early Parkinson's disease partnered with Roche, and coramitug for ATTR cardiomyopathy partnered with Novo. Roche is expected to initiate its Phase 3 in Q4 2025, while Novo has already initiated its Phase 3.
- The company anticipates earning up to $105 million in clinical milestones in 2026 related to coramitug reaching a certain number of enrolled patients.
- A decision from Bristol on the PRX019 Phase 1 program is also expected later in 2026.
- Prothena's distributable reserves were approved to support a share repurchase program for 2026.
- Preclinical data for PRX012, an amyloid beta molecule utilizing transferrin receptor technology for Alzheimer's, is expected in 2026.
Dec 4, 2025, 3:50 PM
Prothena Discusses Pipeline Progress and Upcoming Milestones
PRTA
New Projects/Investments
Guidance Update
Share Buyback
- Prothena Corporation has two Phase 3 programs: prasunezumab for early Parkinson's disease partnered with Roche, and coramitug for ATTR cardiomyopathy partnered with Novo. Novo has initiated its Phase 3, and Roche is expected to initiate its Phase 3 in the fourth quarter.
- The company anticipates earning up to $105 million in clinical milestones in 2026, related to coramitug reaching a certain number of enrolled patients and a decision on PRX019 from Bristol.
- A share repurchase program for 2026 was approved following a successful Extraordinary General Meeting (EGM).
- Preclinical data for the transferrin PRX012 molecule for Alzheimer's disease is expected in 2026, and data for the Phase 2 MTBR Tau program (BMS-986446) is anticipated in 2027.
Dec 4, 2025, 3:50 PM
Prothena Highlights Late-Stage Pipeline, Upcoming Milestones, and 2026 Share Repurchase Plan
PRTA
New Projects/Investments
Share Buyback
Guidance Update
- Prothena is advancing a robust pipeline, including two late-stage Phase 3 programs: Prasinezumab for early Parkinson's (partnered with Roche, Phase 3 initiation in Q4) and Coramitug for ATTR cardiomyopathy (partnered with Novo, Phase 3 initiated).
- The company anticipates earning $105 million in clinical milestones from Coramitug and PRX019 by the end of 2026.
- Significant remaining milestone payments include $620 million for Prasinezumab , $1.13 billion for Coramitug (tax-free) , $562.5 million for PRX005 , and $617.5 million for PRX019 , along with tiered royalties for all partnered programs.
- Prothena plans to announce a share repurchase program in 2026 around its Q4 2025 announcement.
- The company is also actively seeking partnerships for unpartnered programs and its CyTOPE technology in 2026.
Dec 3, 2025, 6:00 PM
Quarterly earnings call transcripts for PROTHENA CORP PUBLIC LTD.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more